Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association's (ADA) 84 th Scientific Sessions. The presentation will be delivered by INHALE-3 Study Protocol Chair Dr. Irl B. Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck. “We are excited for the first read-out of results from the largest post-market clinical trial MannKind has conducted with Afrezza in the last 10 years,” said
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years [Yahoo! Finance]Yahoo! Finance
- MannKind Co. (NASDAQ: MNKD) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific SessionsGlobeNewswire
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix [Yahoo! Finance]Yahoo! Finance
- MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With PulmatrixGlobeNewswire
MNKD
Earnings
- 5/8/24 - Beat
MNKD
Sec Filings
- 5/29/24 - Form 4
- 5/21/24 - Form 4
- 5/21/24 - Form 4
- MNKD's page on the SEC website